Pertinax Pharma Ltd is a Bristol based biomedical company developing medical, healthcare and veterinary applications of a novel, proprietary long acting formulation of the already widely used antimicrobial drug chlorhexidine (CHX). Broad spectrum CHX is effective and safe but historically its broader clinical use and efficacy has been limited by its short duration of activity which is typically less than 12 hours. This limitation is overcome by Pertinax™ technology, which extends the duration of action to weeks, months or years.

1. Pertinax: A range of novel, controlled release
chlorhexidine materials
Company Presentation May 2018

2. Company Overview
 What is Pertinax?
 Our Target Markets
 Proof of Principle Studies
 Application Focus
 I.P Considerations
 Our Business Model
 The Pertinax Team

3. What is Pertinax?
 A platform technology, Pertinax materials provide sustained, controlled release
of chlorhexidine
 The duration of efficacy and the dose can be controlled using formulation
parameters
 Different variants are available providing different release rates
 Pertinax is a finely divided white solid and can be used in dry, water and
solvent-based products

4. Pertinax
Veterinary
Industrial
Dental and
oral
Ortho-paedic
Medical
devices
Wounds
Markets

5. Primary target market is human wounds
 Many barrier products, dressings and related antimicrobial products on the market:
• Ag, PHMB, Triclosan – concerns over toxicity, bioaccumulation, efficacy and
longevity
• Pressure to reduce antibiotic use
 Market intelligence indicates a demand for an alternative antimicrobial
 Chlorhexidine is familiar to clinicians
 Controlled dose gives superior efficacy and safety using Pertinax

6. Pertinax
Polymer
films
Biomedical
cements
Silicones
Sutures
Polymer
foams
Aerosols
and sprays
Materials for which Proof of Principle has been achieved

7. Wound care materials: sutures
0
1
2
3
4
5
6
7
8
9
10
Pertinax suture 1 (PGA) Pertinax suture 2 (V) Triclosan suture (VP)
E.coliZOI(mm)
No aging 24 h aging
Pertinax suture
shows a zone of
inhibition
Control suture has
no zone of
inhibition
Pertinax sutures have an antimicrobial efficacy that withstands aging, whereas commercial sutures do not

8. Wound dressing materials: polyurethane foam
1.E+00
1.E+01
1.E+02
1.E+03
1.E+04
1.E+05
1.E+06
1.E+07
1.E+08
1.E+09
1.E+10
0 h 24 h
S.aureusCFU/mL
Control PU foam 2% Pertinax foam
Pertinax PU foams give total kill of S. aureus using the standard AATCC 100 test for antimicrobial fabrics

9. Wound dressing materials: acrylic
1.E+00
1.E+01
1.E+02
1.E+03
1.E+04
1.E+05
1.E+06
1.E+07
1.E+08
S.aureusCFU/mL
Efficacy at 4 hours
Control acrylic
5% Pertinax acrylic 1
5% Pertinax acrylic 2
5% Pertinax acrylic 3
Pertinax acrylic gives a substantial 103+ reduction in bacterial counts after only 4 hours

10. Topical applications: Pertinax aerosol spray
Pertinax aerosol sprays provide a flexible, water-resistant, translucent polymer film containing Pertinax particles
Pertinax aerosol spray applied to an artificial skin material. (1) after
application, (2) after 15 min in vigorously agitated water, (2) after 30 min in
vigorously agitated water
1 2 3
The sprayed film is very flexible
without flaking when dry or wet

11. How is Pertinax protected?
 Pertinax materials are a series of novel salts of chlorhexidine
 Core patent covers substance of matter, providing strong protection
 Patent granted in the UK (2015) and USA (2017) and in inspection phase in other
territories
 IP licensed to company on an exclusive, royalty free licence from University of Bristol
and will assigned on completion of financial milestones
 “Pertinax” Trademark granted in UK and US

12. What is our business model?
 B2B relationship with OEM and end manufacturers in target markets
 Joint Development Projects/Agreements typical first step after proof of principle
 Early projects conducted with non-GMP material manufactured in house
 Ultimately Pertinax will act as the supplier, via our CMO, of cGMP Pertinax materials
to use in partners’ products
 License fees/royalty payments agreed as part of partnership arrangement

13. Our Team
Michele Barbour, CEO
Michele is academic founder of Pertinax and the inventor of Pertinax technology. A respected
materials scientist, she is also Reader in Biomaterials at the University of Bristol
Stuart Gibson, CFO
Stuart has worked in multiple technology growth companies and having raised investment from
venture capital, private equity and negotiated M&A and successful exits
Chris Nicklin, Operations and Technical Consultant
Chris has a wealth of technical operations expertise in pharmaceutical, fine chemical and life
science sectors. He provides process development and scale up expertise for Pertinax
Paul Williams, Business Development Manager
Paul brings business development expertise from his roles within companies in wound care and
medical device

14. Any Questions
Contact: pwilliams@pertinaxpharma.com
www.pertinaxpharma.com